Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126931671 | 12693167 | 1 | I | 20120309 | 20160829 | 20160829 | EXP | KR-CIPLA LTD.-2016KR17458 | CIPLA | 0.00 | Y | 0.00000 | 20160829 | OT | KR | KR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126931671 | 12693167 | 1 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | UNK | Y | U | 0 | ||||||||
| 126931671 | 12693167 | 2 | SS | Etanercept | ETANERCEPT | 1 | Unknown | UNK | U | U | 0 | ||||||||
| 126931671 | 12693167 | 3 | C | Sulphasalzine | 2 | Unknown | UNK | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126931671 | 12693167 | 1 | Antiviral prophylaxis |
| 126931671 | 12693167 | 2 | Ankylosing spondylitis |
| 126931671 | 12693167 | 3 | Ankylosing spondylitis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126931671 | 12693167 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126931671 | 12693167 | Hepatitis B DNA increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |